PVLA 10-Q: SEC filing
Palvella Therapeutics
Filed with the SEC on · accession 0001193125-26-448638
PVLA filed a 10-Q (quarterly report) with the SEC on Nov 5, 2026. The quarterly report: unaudited results for the quarter plus management’s comments. The stock moved -3.3% by the first close after the filing.
Summary of the filing
Palvella Therapeutics filed its quarterly 10-Q report for the period ending September 30, 2026, disclosing financial results and pipeline updates for its QTORIN rapamycin programs targeting angiokeratomas, microcystic LMM, and cutaneous venous malformations.
Key details
How PVLA stock reacted
Close before
$162.28
Nov 4, 2026
First close after
-3.35%
$156.85
5 trading days
—
Since filing
—
✦ Ask GOAX AI about this filing — what it means for PVLA, what changed since its last filings and what to watch next.
Try it free for 7 days🔔 Want to stay updated on new SEC filings for PVLA?
Click hereFrequently asked questions
What did PVLA file with the SEC on Nov 5, 2026?
PVLA filed a 10-Q (SEC filing). Palvella Therapeutics filed its quarterly 10-Q report for the period ending September 30, 2026, disclosing financial results and pipeline updates for its QTORIN rapamycin programs targeting angiokeratomas, microcystic LMM, and cutaneous venous malformations.
How do I read a 10-Q?
The quarterly report: unaudited results for the quarter plus management’s comments. Compare revenue, margins and cash flow with the same quarter last year. Check MD&A for guidance changes and what drove the quarter.
Why are SEC filings important?
Public companies must tell the SEC about anything that can change their value — results, leadership changes, big deals, new shares, bankruptcy. Filings are the official source, often before the news. A 10-Q (quarterly report): The quarterly report: unaudited results for the quarter plus management’s comments.
How did PVLA stock react to this filing?
PVLA closed at $162.28 before the filing and $156.85 on Nov 5, 2026 (-3.35%).
Other PVLA SEC filings
Get alerts when PVLA files with the SEC, plus live charts, key levels and news for 13,000+ stocks.
Try SEPT free for 7 days